Use this space to put some text. Update this text in HTML Powered by Blogger.
There was an error in this gadget

Thursday, 19 February 2015

Sensex, Nifty tumble; Hindalco, BHEL, GAIL gain 1-2%

10:30am Aurobindo Pharma rallies

Shares of Aurobindo Pharma gained 3 percent as Bank of America Merrill Lynch reiterated its buy rating on the stock. The brokerage house sees 38 percent upside potential from current price level.

Aurobindo corrected 20 percent over the past few days due to weak Q3FY15 operational performance. Operational performance was hit due to one-off expenses such as mark-to-market losses on inventory and one-time penalty for non-supply of products.

The brokerage believes the drug maker has multiple levers of growth such as strong US pipeline, turnaround of WE business and positive contribution of Natrol acquisition. Hence, it sees the current weakness in the stock as a particularly good buying opportunity.

10:00am Market Check

Dragged by index heavyweights, the market is crumbling down. The Sensex is down 235.25 points at 29227.02 and the Nifty is down 65.20 points at 8830.10. About 1025 shares have advanced, 874 shares declined, and 162 shares are unchanged.

Reliance, ICICI Bank, HDFC, Tata Power and Axis Bank are major losers in the Sensex. Among the gainers are Hindalco, BHEL, Tata Steel, GAIL and Sesa Sterlite.

Japanese stocks rose to a fresh 15-year high and the dollar was on the front foot again on upbeat US data, but continuing uncertainty over the Greek debt negotiations weighed on the euro.

US weekly jobless numbers released overnight proved better than expected, diffusing some of the pressure on the dollar that followed dovish-sounding minutes from the last Federal Reserve policy meeting. The minutes had dented expectations for an early interest rate hike by the Fed, driving US debt yields and the dollar lower.

The greenback was also supported as the ebb and flow of confidence in the difficult talks between Greece and its lenders capped the euro. More information please visit this site

No comments:

Post a Comment